NCT05034874: A reported trial by InterveXion Therapeutics, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05034874 |
|---|---|
| Title | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 9, 2022 |
| Completion date | Sept. 11, 2023 |
| Required reporting date | Sept. 10, 2024, midnight |
| Actual reporting date | Aug. 30, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |